Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia
1 other identifier
interventional
15
1 country
1
Brief Summary
Cognitive impairments in schizophrenia are the most debilitating aspect of the illness and poorly treated by current medications. This study investigates transcranial direct current stimulation (tDCS) - a safe, noninvasive weak electrical current delivery to stimulate brain function - as a novel therapeutic for cognition in schizophrenia. Integrating neurostimulation, electrophysiology and neuroimaging, this project aims to study tDCS effects on cognition by verifying therapeutic target engagement, evaluating the tolerability of tDCS sessions, and optimizing treatment parameters.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable schizophrenia
Started Nov 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 23, 2016
CompletedFirst Posted
Study publicly available on registry
November 29, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2019
CompletedResults Posted
Study results publicly available
November 25, 2020
CompletedNovember 25, 2020
November 1, 2020
2.6 years
November 23, 2016
June 29, 2020
November 4, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging
Change from Baseline to week 1 as measured by modulation of fMRI BOLD signal in DLPFC in the context of cognitive control task performance.
1 week
tDCS Engagement of DLPFC Activity Indexed by Modulation of Frontal Cortical Gamma Oscillations
Change from Baseline to week 1 as measured by EEG frontal gamma oscillations in the context of cognitive control task performance
1 week
Secondary Outcomes (2)
Optimal tDCS Strength for DLPFC Engagement
1 Week
Tolerability and Feasibility of Multi-session tDCS in Schizophrenia
1 week
Study Arms (4)
2.5mA
EXPERIMENTALActive stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
2.0mA
EXPERIMENTALActive stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
1.5mA
EXPERIMENTALActive stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
0mA
SHAM COMPARATORThis will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
Interventions
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Eligibility Criteria
You may qualify if:
- ages 18-35 years;
- within first five years of antipsychotic treatment;
- on stable doses of antipsychotic medication for at least one month;
- Clinically stable as defined by Clinical Global Impression-Severity scale (CGI-S) less than or equal to 4 (moderately ill);
- Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores \<40);
- DSM-5 MINI 7.0.2 criteria for schizophrenia or schizoaffective by patient SCID
You may not qualify if:
- Mental retardation as defined by pre-morbid IQ by Wechsler Test of Adult Reading at screening \<70 or Spanish Word Accentuation Test;
- significant head injury;
- History of severe medical or neurological illnesses
- pregnancy or postpartum (\<6 weeks after delivery or miscarriage);
- inability to provide informed consent;
- significant color blindness that affects task performance;
- Positive urine drug screen (exception for marijuana) or presence of substance use disorder within 1 month;
- Currently on benzodiazepines or mood stabilizers affecting GABA
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Baylor College of Medicine
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Despite concerted and exhaustive subject recruitment efforts, the total number of patients completing the protocol was minimal. As such the sample size was inadequate for deriving any meaningful descriptive statistics or statistical comparisons.
Results Point of Contact
- Title
- Raymond Cho
- Organization
- Baylor College of Medicine
Study Officials
- PRINCIPAL INVESTIGATOR
Raymond Cho, M.D., M.Sc.
Baylor College of Medicine
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 23, 2016
First Posted
November 29, 2016
Study Start
November 1, 2016
Primary Completion
June 1, 2019
Study Completion
June 1, 2019
Last Updated
November 25, 2020
Results First Posted
November 25, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will share
Data will be open to sharing after primary findings of study have been published